Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Miconazole 20mg/g oromucosal gel sugar free
1203020H0AAAAAA
|
Miconazole (Mouthwash) | Miconazole | Ear, Nose and Oropharynx | 16,423 |
|
Azelastine 140micrograms/dose nasal spray
1202010A0AAABAB
|
Azelastine hydrochloride (Nasal) | Azelastine hydrochloride | Ear, Nose and Oropharynx | 16,420 |
|
Difflam Oral Rinse 0.15% solution
1203010E0BBAAAA
|
Difflam (Mouthwash) | Benzydamine hydrochloride | Ear, Nose and Oropharynx | 15,269 |
|
Gentamicin 0.3% / Hydrocortisone acetate 1% ear drops
1201010G0AAACAC
|
Hydrocortisone acetate (Ear) | Hydrocortisone acetate | Ear, Nose and Oropharynx | 14,985 |
|
Ciprofloxacin 2mg/ml ear dps 0.25ml ud preservative free
1201010ACAAABAB
|
Ciprofloxacin (Ear) | Ciprofloxacin | Ear, Nose and Oropharynx | 12,609 |
|
Sofradex ear/eye drops
120101040BBAAAA
|
Sofradex (Drops) | Dexamethasone sodium metasulphobenzoate | Ear, Nose and Oropharynx | 11,887 |
|
Triamcinolone 55micrograms/dose nasal spray
1202010T0AAAAAA
|
Triamcinolone acetonide (Nasal) | Triamcinolone acetonide | Ear, Nose and Oropharynx | 10,236 |
|
Betamethasone 0.1% / Neomycin 0.5% ear/eye/nose drops
1201010E0AAABAB
|
Betamethasone sodium phosphate (Ear) | Betamethasone sodium phosphate | Ear, Nose and Oropharynx | 9,962 |
|
Flixonase Nasule 400microgram/unit dose nasal drops
1202010M0BBABAB
|
Flixonase | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | 8,818 |
|
Saline Steripoules nebuliser liquid 2.5ml unit dose ampoules
1202020L0BJABCC
|
Saline Steripoule (Galen) | Sodium chloride | Ear, Nose and Oropharynx | 8,622 |
|
Corsodyl 0.2% mouthwash alcohol free
1203040E0BBAIAB
|
Corsodyl | Chlorhexidine gluconate | Ear, Nose and Oropharynx | 6,325 |
|
Flumetasone 0.02% / Clioquinol 1% ear drops
1201010F0AAAAAA
|
Flumetasone pivalate | Flumetasone pivalate | Ear, Nose and Oropharynx | 6,196 |
|
Otigo 40mg/g / 10mg/g ear drops
1201010AGBBAAAA
|
Otigo | Phenazone/lidocaine | Ear, Nose and Oropharynx | 6,059 |
|
Pilocarpine 5mg tablets
1203050P0AAABAB
|
Pilocarpine hydrochloride (Systemic) | Pilocarpine hydrochloride | Ear, Nose and Oropharynx | 6,053 |
|
EarCalm 2% spray
1201010B0BBAAAF
|
EarCalm | Acetic acid | Ear, Nose and Oropharynx | 5,681 |
|
Corsodyl Mint 0.2% mouthwash
1203040E0BBACAB
|
Corsodyl | Chlorhexidine gluconate | Ear, Nose and Oropharynx | 5,530 |
|
Hydrocortisone 2.5mg muco-adhesive buccal tablets sugar free
1203010M0AAAAAA
|
Hydrocortisone (Mouthwash) | Hydrocortisone (Sodium succinate) | Ear, Nose and Oropharynx | 5,393 |
|
Xylometazoline 0.1% nasal spray
1202020P0AAACAC
|
Xylometazoline hydrochloride | Xylometazoline hydrochloride | Ear, Nose and Oropharynx | 5,125 |
|
Rinaspray 21micrograms/dose nasal spray
1202020I0BBABAB
|
Rinatec | Ipratropium bromide | Ear, Nose and Oropharynx | 5,122 |
|
Mometasone 25microg / Olopatadine 600microg/dose nsl spy
1202010Z0AAAAAA
|
Mometasone furoate/olopatadine hydrochloride | Mometasone furoate/olopatadine hydrochloride | Ear, Nose and Oropharynx | 4,987 |
|
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray
1202010Z0BBAAAA
|
Ryaltris | Mometasone furoate/olopatadine hydrochloride | Ear, Nose and Oropharynx | 4,432 |
|
Nasacort 55micrograms/dose nasal spray
1202010T0BBAAAA
|
Nasacort | Triamcinolone acetonide | Ear, Nose and Oropharynx | 4,304 |
|
Phenazone 40mg/g / Lidocaine 10mg/g ear drops
1201010AGAAAAAA
|
Phenazone/lidocaine | Phenazone/lidocaine | Ear, Nose and Oropharynx | 4,139 |
|
Saline 0.9% neb liq 2.5ml Steri-Neb unit dose ampoules
1202020L0BCAACC
|
Saline Steri-Neb | Sodium chloride | Ear, Nose and Oropharynx | 3,876 |
|
Bactroban 2% nasal ointment
1202030R0BBAAAA
|
Bactroban (Nasal) | Mupirocin | Ear, Nose and Oropharynx | 3,850 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.